| Literature DB >> 29066308 |
Zhe Chen1, Bryan D Cox1, Ethel C Garnier-Amblard2, Tamara R McBrayer2, Steven J Coats2, Raymond F Schinazi3, Franck Amblard4.
Abstract
Several β-d-2'-deoxy-2'-substituted nucleoside analogs have displayed potent and selective anti-HCV activities and some of them have reached human clinical trials. In that regard, we report herein the synthesis of a series of 2'-deoxy,2'-dibromo substituted U, C, G and A nucleosides 10a-d and their corresponding phosphoramidate prodrugs 13a-d. The synthesized nucleosides 10a-d and prodrugs 13a-d were evaluated for their inhibitory activity against HCV as well as cellular toxicity. The results showed that the most potent compound was prodrug 13a, which exhibited micromolar inhibitory activity (EC50 = 1.5 ± 0.8 µM) with no observed toxicity. In addition, molecular modeling and free energy perturbation calculations for the 5'-triphosphate formed from 13a and related 2'-modified nucleotides are discussed.Entities:
Keywords: Hepatitis C virus; Nucleoside; Prodrug; Synthesis
Mesh:
Substances:
Year: 2017 PMID: 29066308 PMCID: PMC5693771 DOI: 10.1016/j.bmcl.2017.10.024
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823